Education
About Us
Working with TipRanks
Follow Us
Glenmark Pharmaceuticals Limited (IN:GLENMARK)
:GLENMARK
Total Valuation
Glenmark Pharmaceuticals Limited has a market cap or net worth of ₹521.13B. The enterprise value is ―.
Market Cap₹521.13B
Enterprise Value―
Share Statistics
Glenmark Pharmaceuticals Limited has 282,200,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding282,200,800
Owned by Insiders―
Owned by Institutions0.05%
Financial Efficiency
Glenmark Pharmaceuticals Limited’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 26.41%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)26.41%
Return on Capital Employed (ROCE)0.41
Revenue Per Employee8.92M
Profits Per Employee933.49K
Employee Count14,989
Asset Turnover0.83
Inventory Turnover1.49
Valuation Ratios
The current PE Ratio of Glenmark Pharmaceuticals Limited is 69.1. Glenmark Pharmaceuticals Limited’s PEG ratio is -0.26.
PE Ratio69.1
PS Ratio3.19
PB Ratio4.81
Price to Fair Value4.81
Price to FCF-27.00
Price to Operating Cash Flow0.00
PEG Ratio-0.26
Income Statement
In the last 12 months, Glenmark Pharmaceuticals Limited had revenue of 133.63B and earned 10.47B in profits. Earnings per share was 37.11.
Revenue133.63B
Gross Profit88.38B
Operating Income41.84B
Pretax Income13.99B
Net Income10.47B
EBITDA21.68B
Earnings Per Share (EPS)37.11
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Glenmark Pharmaceuticals Limited pays an annual dividend of ₹2.5, resulting in a dividend yield of 0.27%
Dividend Per Share₹2.5
Dividend Yield0.27%
Payout Ratio11.28%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change23.81%
50-Day Moving Average1.92K
200-Day Moving Average1.72K
Relative Strength Index (RSI)51.96
Average Volume (3m)28.97K
Important Dates
Glenmark Pharmaceuticals Limited upcoming earnings date is Feb 13, 2026, During Market Hours (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateFeb 13, 2026
Ex-Dividend DateOct 03, 2025
Financial Position
Glenmark Pharmaceuticals Limited as a current ratio of 1.56, with Debt / Equity ratio of 0.00%
Current Ratio1.56
Quick Ratio1.05
Debt to Market Cap0.05
Net Debt to EBITDA0.37
Interest Coverage Ratio20.20
Taxes
In the past 12 months, Glenmark Pharmaceuticals Limited has paid 3.52B in taxes.
Income Tax3.52B
Effective Tax Rate0.25
Enterprise Valuation
Glenmark Pharmaceuticals Limited EV to EBITDA ratio is 20.02, with an EV/FCF ratio of -27.51.
EV to Sales3.25
EV to EBITDA20.02
EV to Free Cash Flow-27.51
EV to Operating Cash Flow-52.42
Balance Sheet
Glenmark Pharmaceuticals Limited has ₹17.05B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of ₹17.05B billion.
Cash & Marketable Securities₹17.05B
Total Debt₹0.00
Net Cash₹17.05B
Net Cash Per Share₹60.43
Tangible Book Value Per Share₹261.84
Margins
Gross margin is 66.72%, with operating margin of 31.31%, and net profit margin of 7.84%.
Gross Margin66.72%
Operating Margin31.31%
Pretax Margin10.47%
Net Profit Margin7.84%
EBITDA Margin16.22%
EBIT Margin14.27%
Analyst Forecast
The average price target for Glenmark Pharmaceuticals Limited is ₹1,935.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target₹1,935.00
Price Target Upside2.85% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast30.27%
EPS Growth Forecast―